Fourth quarter revenues of $60.7 million, in line with previous guidanceFourth quarter GAAP net income of $2.2 million; non-GAAP net income of ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...